September 2026 FDA Recall Fosfomycin Tromethamine by Cipla Usa, Inc.
D-0014-2027 - Failed Impurities/Degradation Specifications

This Class II drug recall was voluntarily initiated by Cipla Usa, Inc. on September 18, 2026 for the product Fosfomycin Tromethamine. The FDA reported the reason for recall as failed impurities/degradation specifications. The product was distributed Nationwide and the recall is currently ongoing.

Recall Number: D-0014-2027

Reason for Recall
Failed Impurities/Degradation Specifications
Initiated
09-18-2026
Reported
10-14-2026
Quantity
N/A

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Fosfomycin Tromethamine Granules for Oral Solution, (Equivalent to 3 Grams of Fosfomycin), 1 Single-Dose Sachet, Rx only, Manufactured by: Cipla Ltd., Kurkumbh-413802, Maharashtra, India, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, NDC 69097-579-67.

Batch or Lot Expiration Information

Lot# : 5KA0405, Exp 12/31/2026.

Affected Packages Involved in this Recall